- Home
- NXTS vs CDIO Comparison
NXTS vs CDIO Comparison
Compare NXTS & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXTS | CDIO |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NXTS | CDIO |
|---|---|---|
| Price | $0.92 | $4.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.6K | ★ 6.7M |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,434.82 |
| Revenue Next Year | N/A | $4,661.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $0.18 |
| 52 Week High | $1.00 | $7.91 |
Technical Indicators
Market Signals| Indicator | NXTS | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 64.21 |
| Support Level | N/A | $3.40 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.93 |
| MACD | 0.00 | 0.32 |
| Stochastic Oscillator | 0.00 | 52.08 |
Price Performance
Historical ComparisonAbout CDIO Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.